首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Human papillomavirus type specific risk of progression and remission during long‐term follow‐up of equivocal and low‐grade HPV‐positive cervical smears
【24h】

Human papillomavirus type specific risk of progression and remission during long‐term follow‐up of equivocal and low‐grade HPV‐positive cervical smears

机译:人类乳头瘤病毒型进展的特定风险和缓解的长期随访期间的等焦点和低级HPV阳性颈涂片

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The prevalence of clinically relevant HPV types and their specific risk for progression and regression in women with atypical squamous cells of uncertain significance (ASCUS) and low‐grade squamous intraepithelial lesions (LSIL) were studied in a routine screening population. A 4‐year cohort of women ( n ?=?820) with ASCUS/LSIL and a positive HPV test in triage were followed for 6–9 years. The progression risks for CIN2+/CIN3+ were determined for single (71.2%) and multiple HPV infections (28.8%). The CIN2+ progression risk for all HPV 16, all HPV 35, single HPV 16 and single HPV 35 infections were 65.3% (95% CI: 59.6–71.0), 64.4% (95% CI: 50.4–78.4), 63.8% (95% CI: 56.2–71.4) and 73.7% (95% CI: 53.9–93.5), respectively. Based on CIN2+ progression risks four main groups were defined; the HPV 16 group, the HPV 31/33/35 group, the HPV 18/45/51/52 group and the HPV 39/56/58/59/66/68 group with progression risks of 65.3% (95% CI: 59.6–71.0), 62.1% (95% CI: 54.8–69.4), 52.6 (95% CI: 45.9–59.3) and 39.5 (95% CI: 33.0–46.0), respectively. In multivariate analyses, women in the age group 40–49 years had an increased risk of CIN2+ progression. As for CIN3+, HPV 16 had a higher progression risk than other HPV risk groups ( p ??0.05). In multiple infections only HPV 16 had a significant additive CIN3+ progression risk ( p ??0.05) as compared to other HPV risk groups. In summary, HPV types 16 and 35, including the HPV risk group 31/33/35, had a similar CIN2+ progression risk, but only HPV 16 had a higher risk for CIN3+ progression.
机译:在常规筛选人群中,研究了临床相关HPV类型的临床相关HPV类型的普遍性及其进展和消退的具体风险和患有不确定鳞状细胞和低级鳞状上皮病变(LSIL)的患者。遵循4年的女性队伍(N?=?820)和分类中的阳性HPV测试,6-9岁。 CIN2 + / CIN3 +的进展风险针对单身(71.2%)和多次HPV感染(28.8%)确定。所有HPV 16,所有HPV 35,单HPV 16和单HPV 35感染的CIN2 +进展风险为65.3%(95%CI:59.6-71.0),64.4%(95%CI:50.4-78.4),63.8%(95 %CI:56.2-71.4)和73.7%(95%CI:53.9-93.5)。基于CIN2 +进展风险,定义了四个主要群体; HPV 16组,HPV 31/33/35组,HPV 18/45/51/52和HPV 39/56/58/59/66/68,具有65.3%的进展风险(95%CI: 59.6-71.0),62.1%(95%CI:54.8-69.4),52.6(95%CI:45.9-59.3)和39.5(95%CI:33.0-46.0)。在多变量分析中,年龄组的女性40-49岁的患者风险增加了CIN2 +进展。至于CIN3 +,HPV 16的进展风险高于其他HPV风险群(P?& 0.05)。在多种感染中,与其他HPV风险组相比,只有HPV 16具有显着的添加剂CIN3 +进展风险(P?&Δ05)。总之,HPV类型16和35,包括HPV风险组31/33/35具有类似的CIN2 +进展风险,但只有HPV 16的CIN3 +进展具有更高的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号